SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001516551-24-000067
Filing Date
2024-07-05
Accepted
2024-07-05 08:58:38
Documents
3
Period of Report
2024-07-02

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1720184311.html 3  
1 FORM 3 wk-form3_1720184311.xml 3 1612
2 EX-24.1 skye_ksxpoa.htm EX-24.1 3511
3 GRAPHIC skye_ksxpoa001.jpg GRAPHIC 226084
  Complete submission text file 0001516551-24-000067.txt   318369
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Issuer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O JAZZ PHARMACEUTICALS PLC 5TH FL, WATERLOO EXCHANGE, WATERLOO RD DUBLIN L2 4 L2
Business Address
Smith Karen L. (Reporting) CIK: 0001639637 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-42009 | Film No.: 241101721